

For Immediate Release

Pasture Holdings Ltd. successfully debuts on the Catalist Board of the SGX-ST

- Strong support from the medical community with placement shares taken up by prominent industry figures
- IPO proceeds will be utilised for business expansion through the strengthening of existing business segments, geographical diversification, and potential business collaboration opportunities
- Private label supply agreement with McKesson will expand Pasture's medical supplies product portfolio and broaden its global distribution network
- Strong upside potential from industry tailwinds such as efforts by the Singapore government to stockpile medical supplies, growing ageing population, and rising global healthcare expenditure

Singapore, 9 June 2023 – Pasture Holdings Ltd. ("**Pasture**" or the "**Company**", and together with its subsidiaries, the "**Group**"), a global pharmaceutical products and medical supplies and devices company, made its debut on the Catalist Board of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") today under the ticker symbol "15W4".

Through the initial public offering ("**IPO**"), the Company has successfully raised S\$5.0 million from the 20.0 million placement shares offered. Notable investors include prominent industry figures from the medical field such as Draagonfly LLP, an entity held by the family of Cordlife Group Limited's Vice Chairman, Dr. Ho Choon Hou, gynecologic oncologist, Dr. Tay Eng Hseon, and ophthalmologist, Dr. Chng Nai Wee of Eagle Eye Centre.

Pasture intends to utilise the IPO proceeds primarily to strengthen its existing business segments and expand its global footprint by diversifying into key growth markets. In addition, the Group will continue its efforts in exploring business collaboration opportunities to expand its distribution channels and product portfolio.

In October 2022, Pasture signed a private label supply agreement with McKesson Medical-Surgical Inc. ("**McKesson**") for the supply of medical and surgical supplies and devices to the Group. McKesson is a subsidiary of McKesson Corporation, one of the largest medical and pharmaceutical distribution companies globally and among the top 10 Fortune 500 companies in the United States¹.

The agreement with McKesson has significantly expanded Pasture's medical supplies portfolio, where the Group is currently able to provide customers with access to a portfolio of over 1,200 medical supplies and devices to meet their demands within the value chain of the global healthcare system and broaden the Group's global distribution outreach to other countries and regions.

Apart from new geographical market segments, Pasture is able to tap on opportunities that may arise across its various business segments which are complementary to one another. For instance, the Group intends to capitalise on its established presence in existing market segments, its robust supply chain network that spans over 50 countries and its strong marketing and distribution capabilities.

¹ Source: Fortune, Fortune 500, 2022.

Pasture currently supplies over 1,000 third-party pharmaceutical products, as well as develops, markets, and sells its own proprietary range of masks, *Pasture Masks*. With a comprehensive suite of products under one roof, the Group believes it will be able to cement its position as a well-known global wholesaler and distributor of pharmaceutical products and medical supplies and devices.

In addition, the Group is also looking to further develop two complementary business verticals, namely, its own range of oral disintegrating strips under the brand *Hart-S ODS* and a mobile application for pet health and nutrition services, *furlife*.

In the near term, Pasture could benefit from the medical supplies stockpiling efforts by the Singapore government. In the long run, the Group is well-positioned to ride on favourable industry trends, such as the growing ageing population in developed nations and the increase in global healthcare expenditure.

Mr. Lloyd Soong, the Executive Chairman and Chief Executive Officer of Pasture commented, *“The support shown by our new investors has been extremely encouraging. The fact that some of our anchor investors are key figures in Singapore’s medical industry is a vote of confidence in the Group’s business prospects and strategies. All in all, we aim to build a strong platform through this listing exercise and are eager to kickstart this next phase of our multi-faceted growth journey.”*

##



About Pasture Holdings Ltd.

Pasture is a Singapore-based, global pharmaceutical products and medical supplies and devices company. Having supplied to over 50 countries, the Group has a comprehensive portfolio of over 1,000 third-party pharmaceutical products and over 1,200 medical supplies and devices. In addition, Pasture develops, markets and sells its own proprietary range of masks under the *Pasture Masks* brand and, as part of its pharmaceutical wholesale and drop-shipment business, specialises in cold-chain management services relating to temperature-sensitive pharmaceutical products. The Group is also involved in other new complementary products and services such as *Hart-S ODS*, its own range of oral disintegrating strips and *furlife*, a mobile application for pet health services.

For more information, please visit <https://pasturegroup.com/>

Issued for and on behalf of Pasture Holdings Ltd.

By Financial PR

For more information, please contact

Kamal SAMUEL / Shivam SARAF / Hong Ee TANG

E-mail: kamal@financialpr.com.sg / shivam@financialpr.com.sg / hongee@financialpr.com.sg

Tel: 6438 2990

Pasture Holdings Ltd. (the “**Company**”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) on 9 June 2023. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”).

This press release and its contents have been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

IMPORTANT NOTICE

This press release is for information only and does not constitute or form part of an invitation, solicitation or offer to acquire, purchase or subscribe for any securities in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied upon in any connection with, any contract, commitment or investment decision whatsoever.

The information in this press release is qualified in its entirety by, and should be read in conjunction with, the full text of the offer document of the Company dated 31 May 2023 (“**Offer Document**”) which has been registered with the SGX-ST, acting as agent on behalf of the Monetary Authority of Singapore (the “**MAS**”). Capitalised terms used herein, unless otherwise defined in this press release, shall bear the same meanings ascribed to them in the Offer Document. Any decision to invest in the Placement Shares should be made solely on the basis of information contained in the Offer Document and no reliance should be placed on any information other than that contained in the Offer Document. A potential investor should carefully read the Offer Document first, and in particular, the section on “Risk Factors” for a discussion of certain factors to be considered, and make his own assessment before deciding whether to invest in the Placement Shares.

An investment in the Placement Shares is subject to various risks and uncertainties, including the potential loss of the principal amount invested. Listing of the Shares on the Catalist Board of the SGX-ST does not guarantee that an active public market for the Shares will develop. This press release may contain forward-looking statements that involve risks, uncertainties and assumptions. Actual future performance, outcomes and results could differ materially from those expressed in forward-looking statements and financial information as a result of a number of risks, uncertainties and assumptions. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which reflect the Company's current views concerning future events. No representations or warranties are made as to the accuracy or reasonableness of these forward-looking statements. Certain of the information in this media release is historical information. The past performance of the Group is not indicative of its future performance.

This press release may be restricted by law in certain jurisdictions. Persons who may come into possession of this press release are advised to consult with their own legal advisers as to what restrictions may be applicable to them and to observe such restrictions. This press release may not be used for the purpose of an offer or invitation in any circumstances. Neither this press release nor any of its content may be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Information contained in this press release does not constitute a part of the preliminary offer document or the Offer Document. Failure to comply with these restrictions may result in a violation of the applicable laws of other jurisdictions.

This press release has not been examined or reviewed by the MAS or the SGX-ST.